AbbVie
ABBV
£142.50
Share price
-0.53%
Change (1 day)
9.97%
Change (1 year)
Categories
The biotechnology and pharmaceutical company Abbvie, spelled AbbVie, was founded in 2013 as a spin-off from Abbott Laboratories and is traded on the NYSE stock exchange in the S&P 100 index under the symbol “ABBV”.
AbbVie (ABBV) - P/B ratio
P/B ratio as of July 2025 : 231
According to AbbVie's latest financial reports the company has a price-to-book ratio of 5.89005.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.
AbbVie - P/B ratio (from 2012 to 2025)
P/B ratio by year
| Year | P/B ratio | Change |
|---|---|---|
| 2025-12-31 | N/A | -100% |
| 2024-12-31 | 93.5 | 255.34% |
| 2023-12-31 | 26.3 | 59.17% |
| 2022-12-31 | 16.5 | 6.61% |
| 2021-12-31 | 15.5 | 7.36% |
| 2020-12-31 | 14.4 | -190.14% |
| 2019-12-31 | -16.0 | -0.73% |
| 2018-12-31 | -16.1 | -153.29% |
| 2017-12-31 | 30.3 | 37.99% |
| 2016-12-31 | 22.0 | -9.2% |
| 2015-12-31 | 24.2 | -59.56% |
| 2014-12-31 | 59.8 | 220.35% |
| 2013-12-31 | 18.7 | 16.28% |
| 2012-12-31 | 16.0 | |
| 2011-12-31 | N/A |
P/B ratio for similar companies or competitors
| Company | P/B ratio | P/B ratio differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | 1.60 | -99.31% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | 5.55 | -97.60% | 🇺🇸 USA |
 Eli Lilly LLY | 45.1 | -80.47% | 🇺🇸 USA |
 Amgen AMGN | 25.6 | -88.91% | 🇺🇸 USA |
 Gilead Sciences GILD | 7.29 | -96.84% | 🇺🇸 USA |
 Biogen BIIB | 1.15 | -99.50% | 🇺🇸 USA |
 GlaxoSmithKline GSK | 4.56 | -98.03% | 🇬🇧 UK |
 AstraZeneca AZN | 5.52 | -97.61% | 🇬🇧 UK |
 Neurocrine Biosciences
NBIX | 5.27 | -97.72% | 🇺🇸 USA |